Do analysts prefer STVN or BLFS?

BioLife Solutions has a consensus target price of $32.00, indicating a potential upside of 13.84%. Given BioLife Solutions' higher possible upside, analysts clearly believe BioLife Solutions is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83 BioLife Solutions 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

BioLife Solutions (BLFS) Competitors

$28.11 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$28.12 +0.00 (+0.02%)

As of 07/2/2026 04:19 PM Eastern

Compare

BLFS vs. STVN, LIVN, NVST, MMED, and IRTC

Should you buy BioLife Solutions stock or one of its competitors? MarketBeat compares BioLife Solutions with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioLife Solutions include Stevanato Group (STVN), LivaNova (LIVN), Envista (NVST), MiniMed Group (MMED), and iRhythm Technologies (IRTC). These companies are all part of the "medical equipment" industry.

How does BioLife Solutions compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

In the previous week, Stevanato Group had 7 more articles in the media than BioLife Solutions. MarketBeat recorded 7 mentions for Stevanato Group and 0 mentions for BioLife Solutions. Stevanato Group's average media sentiment score of 0.64 beat BioLife Solutions' score of 0.00 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Overall Sentiment
Stevanato Group	Positive
BioLife Solutions	Neutral

Stevanato Group has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.28	€158.21M	€0.59	32.18
BioLife Solutions	$96.21M	14.28	-$4.59M	-$0.08	N/A

BioLife Solutions has a consensus target price of $32.00, indicating a potential upside of 13.84%. Given BioLife Solutions' higher possible upside, analysts clearly believe BioLife Solutions is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Stevanato Group has a net margin of 11.76% compared to BioLife Solutions' net margin of -2.80%. Stevanato Group's return on equity of 10.27% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
BioLife Solutions	-2.80%	1.81%	1.65%

93.2% of BioLife Solutions shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Stevanato Group has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market.

Summary

Stevanato Group beats BioLife Solutions on 11 of the 17 factors compared between the two stocks.

How does BioLife Solutions compare to LivaNova?

BioLife Solutions (NASDAQ:BLFS) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, LivaNova had 3 more articles in the media than BioLife Solutions. MarketBeat recorded 3 mentions for LivaNova and 0 mentions for BioLife Solutions. LivaNova's average media sentiment score of 1.23 beat BioLife Solutions' score of 0.00 indicating that LivaNova is being referred to more favorably in the news media.

Company	Overall Sentiment
BioLife Solutions	Neutral
LivaNova	Positive

BioLife Solutions has higher earnings, but lower revenue than LivaNova. BioLife Solutions is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	14.28	-$4.59M	-$0.08	N/A
LivaNova	$1.39B	3.31	-$242.47M	$1.95	42.88

LivaNova has a net margin of 7.48% compared to BioLife Solutions' net margin of -2.80%. LivaNova's return on equity of 16.48% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-2.80%	1.81%	1.65%
LivaNova	7.48%	16.48%	7.59%

BioLife Solutions presently has a consensus price target of $32.00, suggesting a potential upside of 13.84%. LivaNova has a consensus price target of $80.75, suggesting a potential downside of 3.43%. Given BioLife Solutions' higher possible upside, equities analysts plainly believe BioLife Solutions is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

BioLife Solutions has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

LivaNova beats BioLife Solutions on 11 of the 16 factors compared between the two stocks.

How does BioLife Solutions compare to Envista?

Envista (NYSE:NVST) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Envista presently has a consensus target price of $28.67, suggesting a potential upside of 3.92%. BioLife Solutions has a consensus target price of $32.00, suggesting a potential upside of 13.84%. Given BioLife Solutions' higher possible upside, analysts clearly believe BioLife Solutions is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Envista has a net margin of 2.41% compared to BioLife Solutions' net margin of -2.80%. Envista's return on equity of 7.11% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
BioLife Solutions	-2.80%	1.81%	1.65%

93.2% of BioLife Solutions shares are held by institutional investors. 1.0% of Envista shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Envista has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.65	$47M	$0.41	67.28
BioLife Solutions	$96.21M	14.28	-$4.59M	-$0.08	N/A

In the previous week, Envista had 2 more articles in the media than BioLife Solutions. MarketBeat recorded 2 mentions for Envista and 0 mentions for BioLife Solutions. Envista's average media sentiment score of 0.77 beat BioLife Solutions' score of 0.00 indicating that Envista is being referred to more favorably in the media.

Company	Overall Sentiment
Envista	Positive
BioLife Solutions	Neutral

Envista has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

Summary

Envista beats BioLife Solutions on 10 of the 15 factors compared between the two stocks.

How does BioLife Solutions compare to MiniMed Group?

BioLife Solutions (NASDAQ:BLFS) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, MiniMed Group had 3 more articles in the media than BioLife Solutions. MarketBeat recorded 3 mentions for MiniMed Group and 0 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.00 beat MiniMed Group's score of -0.50 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
BioLife Solutions	Neutral
MiniMed Group	Negative

BioLife Solutions presently has a consensus target price of $32.00, suggesting a potential upside of 13.84%. MiniMed Group has a consensus target price of $21.33, suggesting a potential upside of 36.84%. Given MiniMed Group's stronger consensus rating and higher possible upside, analysts plainly believe MiniMed Group is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

BioLife Solutions has higher earnings, but lower revenue than MiniMed Group. BioLife Solutions is trading at a lower price-to-earnings ratio than MiniMed Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	14.28	-$4.59M	-$0.08	N/A
MiniMed Group	$3.10B	1.41	-$190.97M	-$0.68	N/A

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 19.7% of MiniMed Group shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Comparatively, 2.2% of MiniMed Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MiniMed Group has a net margin of 0.00% compared to BioLife Solutions' net margin of -2.80%. BioLife Solutions' return on equity of 1.81% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-2.80%	1.81%	1.65%
MiniMed Group	N/A	N/A	N/A

Summary

BioLife Solutions beats MiniMed Group on 8 of the 15 factors compared between the two stocks.

How does BioLife Solutions compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

BioLife Solutions has lower revenue, but higher earnings than iRhythm Technologies. BioLife Solutions is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.56	-$44.55M	-$0.86	N/A
BioLife Solutions	$96.21M	14.28	-$4.59M	-$0.08	N/A

93.2% of BioLife Solutions shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioLife Solutions has a net margin of -2.80% compared to iRhythm Technologies' net margin of -3.53%. BioLife Solutions' return on equity of 1.81% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
BioLife Solutions	-2.80%	1.81%	1.65%

In the previous week, iRhythm Technologies had 6 more articles in the media than BioLife Solutions. MarketBeat recorded 6 mentions for iRhythm Technologies and 0 mentions for BioLife Solutions. iRhythm Technologies' average media sentiment score of 0.59 beat BioLife Solutions' score of 0.00 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
iRhythm Technologies	Positive
BioLife Solutions	Neutral

iRhythm Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market.

iRhythm Technologies presently has a consensus target price of $187.38, indicating a potential upside of 48.15%. BioLife Solutions has a consensus target price of $32.00, indicating a potential upside of 13.84%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe iRhythm Technologies is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

BioLife Solutions beats iRhythm Technologies on 9 of the 17 factors compared between the two stocks.

Get BioLife Solutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLFS vs. The Competition

Export

Metric	BioLife Solutions	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.37B	$8.77B	$7.18B	$12.48B
Dividend Yield	N/A	2.45%	2.66%	6.51%
P/E Ratio	-351.33	16.55	28.02	24.70
Price / Sales	14.28	6.92	535.36	97.93
Price / Cash	122.76	18.11	49.26	57.09
Price / Book	3.64	3.53	10.96	6.46
Net Income	-$4.59M	$226.25M	$3.57B	$337.01M
7 Day Performance	-1.90%	1.50%	2.12%	1.69%
1 Month Performance	5.48%	-0.23%	5.25%	3.81%
1 Year Performance	20.85%	-0.49%	33.29%	23.90%

BioLife Solutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLFS BioLife Solutions	2.9936 of 5 stars	$28.11 flat	$32.00 +13.8%	+20.9%	$1.37B	$96.21M	N/A	440	Gap Up
STVN Stevanato Group	3.4131 of 5 stars	€17.75 +2.2%	N/A	-22.8%	€5.40B	€1.34B	30.23	6,010	News Coverage Analyst Downgrade
LIVN LivaNova	1.7258 of 5 stars	$81.13 -2.3%	$80.75 -0.5%	+81.3%	$4.45B	$1.39B	41.51	3,300	Analyst Upgrade
NVST Envista	1.5223 of 5 stars	$26.50 -1.9%	$28.67 +8.2%	+35.3%	$4.30B	$2.72B	64.47	12,000	News Coverage
MMED MiniMed Group	2.2726 of 5 stars	$14.53 -2.4%	$21.33 +46.9%	N/A	$4.08B	$2.99B	N/A	8,000	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLFS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLife Solutions (BLFS) Competitors

BLFS vs. STVN, LIVN, NVST, MMED, and IRTC

How does BioLife Solutions compare to Stevanato Group?

Summary

How does BioLife Solutions compare to LivaNova?

Summary

How does BioLife Solutions compare to Envista?

Summary

How does BioLife Solutions compare to MiniMed Group?

Summary

How does BioLife Solutions compare to iRhythm Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS vs. The Competition

BioLife Solutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLife Solutions (BLFS) Competitors

BLFS vs. STVN, LIVN, NVST, MMED, and IRTC

How does BioLife Solutions compare to Stevanato Group?

Does the media favor STVN or BLFS?

Which has better earnings & valuation, STVN or BLFS?

Do analysts prefer STVN or BLFS?

Is STVN or BLFS more profitable?

Do institutionals & insiders have more ownership in STVN or BLFS?

Which has more risk & volatility, STVN or BLFS?

Summary

How does BioLife Solutions compare to LivaNova?

Does the media refer more to BLFS or LIVN?

Which has higher valuation & earnings, BLFS or LIVN?

Is BLFS or LIVN more profitable?

Do analysts rate BLFS or LIVN?

Which has more risk and volatility, BLFS or LIVN?

Do institutionals and insiders have more ownership in BLFS or LIVN?

Summary

How does BioLife Solutions compare to Envista?

Do analysts prefer NVST or BLFS?

Is NVST or BLFS more profitable?

Do institutionals & insiders hold more shares of NVST or BLFS?

Which has preferable earnings and valuation, NVST or BLFS?

Does the media refer more to NVST or BLFS?

Which has more risk and volatility, NVST or BLFS?

Summary

How does BioLife Solutions compare to MiniMed Group?

Does the media favor BLFS or MMED?

Do analysts prefer BLFS or MMED?

Which has higher earnings and valuation, BLFS or MMED?

Do insiders & institutionals hold more shares of BLFS or MMED?

Is BLFS or MMED more profitable?

Summary

How does BioLife Solutions compare to iRhythm Technologies?

Which has better earnings and valuation, IRTC or BLFS?

Do institutionals & insiders believe in IRTC or BLFS?

Is IRTC or BLFS more profitable?

Does the media prefer IRTC or BLFS?

Which has more volatility and risk, IRTC or BLFS?

Do analysts recommend IRTC or BLFS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS vs. The Competition

BioLife Solutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools